<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722978</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-003</org_study_id>
    <nct_id>NCT04722978</nct_id>
  </id_info>
  <brief_title>Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer</brief_title>
  <official_title>Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer : a Multicenter, Double-blind, Placebo-controlled, Phase 3 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare progression-free survival (PFS) of patients&#xD;
      with metastatic triple-negative breast cancer randomised to treatment with standard&#xD;
      chemotherapy plus moxifloxacin or placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomised, double-blind, placebo-controlled, phase 3 trial. The main&#xD;
      purposes of this study are to examine the efficacy and safety of standard chemotherapy plus&#xD;
      moxifloxacin or placebo as first-line treatment in patients with metastatic triple-negative&#xD;
      breast cancer. This study is designed to recruit up to 228 subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Gemcitabine combined with carboplatin plus moxifloxacin or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>The interval from the date of randomization until the first date on which progression, or death due to any cause</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">228</enrollment>
  <condition>Triple Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine combined with carboplatin plus moxifloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gemcitabine combined with carboplatin plus placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and carboplatin plus antibiotic (moxifloxacin)</intervention_name>
    <description>Standard chemotherapy (gemcitabine and carboplatin) plus antibiotic (moxifloxacin)</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Gemcitabine 1000mg/m^2 IV on days 1 and 8; cycled every 21 days Carboplatin AUC 2 IV on days 1 and 8; cycled every 21 days Moxifloxacin 0.4 PO once daily days 1-5; cycled every 21 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine combined with carboplatin plus placebo</intervention_name>
    <description>Standard chemotherapy (gemcitabine and carboplatin) plus placebo</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Gemcitabine 1000mg/m^2 IV on days 1 and 8; cycled every 21 days Carboplatin AUC 2 IV on days 1 and 8; cycled every 21 days Placebo 0.4 PO once daily days 1-5; cycled every 21 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.&#xD;
&#xD;
          -  Histologically confirmed invasive ductal carcinoma, no specific type (NOS)&#xD;
&#xD;
          -  ER negative and progesterone receptor (PR) negative (defined as &lt; 1% positive cells by&#xD;
             IHC), human epidermal growth factor receptor 2 (HER2) negative (defined as IHC 0-1&#xD;
             staining or fluorescent in situ hybridization (FISH) negative).&#xD;
&#xD;
          -  No prior therapy after first recurrence or diagnosis of metastatic disease.&#xD;
&#xD;
          -  At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid&#xD;
             Tumors (RECIST) criteria.&#xD;
&#xD;
          -  Neutrophil-to-lymphocyte ratios (NLR) in peripheral blood ≥ 2.&#xD;
&#xD;
          -  Adequate organ function including bone marrow, renal function, hepatic function, and&#xD;
             cardiac reserve (Left ventricular ejection fraction (LVEF) by echocardiogram ≥45%).&#xD;
&#xD;
          -  Compliance with the study protocol.&#xD;
&#xD;
          -  Have provided written and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  Definitive breast cancer susceptibility gene (BRCA) mutation, Programmed Cell&#xD;
             Death-Ligand 1 (PD-L1) positive, microsatellite instability-high (MSI-H), and mismatch&#xD;
             repair deficient (dMMR).&#xD;
&#xD;
          -  Patients who are receiving or will receive other biological agents or immunotherapy.&#xD;
&#xD;
          -  Uncontrolled medical problems.&#xD;
&#xD;
          -  Evidence of active acute or chronic infection.&#xD;
&#xD;
          -  Hepatic, renal, cardiac, or bone marrow dysfunction as detailed above.&#xD;
&#xD;
          -  Concurrent malignancy or history of other malignancy within the last five years.&#xD;
&#xD;
          -  Known severe hypersensitivity to moxifloxacin&#xD;
&#xD;
          -  Patients were unable or unwilling to comply with program requirements.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhong-yu Yuan, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhong-yu Yuan, M.D.</last_name>
    <phone>862087342794</phone>
    <email>yuanzhy@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhong-yu Yuan, MD</last_name>
      <phone>86-20-87343794</phone>
      <email>yuanzhygz@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Zhong-yu Yuan</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

